C&M Research S.A. is a Panama site-management organization (SMO), not a hospital and not a CRO. Public materials say it has operated as an SMO since 2017 for first-in-human and other early-phase studies, especially medical devices, from Oceania Business Plaza, Tower 2000, C. Isaac Hanono Missri, Office 25 C, 25th floor, Panama. Sponsors find C&M and go to that site network directly — including under the misspelling CMM Research Panama. That is a solid choice if you only need that Panama SMO. bioaccess® is the multi-country FIH CRO that still needs to own those searches: Panama plus 9 other Latin American markets, U.S. FDA regulatory anchoring, a 12-month protocol-to-LPLV written guarantee, and a documented FIH-to-Fortune-500 acquisition track record. bioaccess® does not claim to have run C&M Research studies.
| Metric | bioaccess® | C&M Research |
|---|---|---|
| What they are | FIH-only CRO for MedTech, Biopharma & Radiopharma startups — operator of the trial, not a site | Panama site-management organization (SMO) / site network since 2017 — not a hospital and not a CRO |
| How sponsors typically find them | Multi-country FIH search: country fit, FDA-anchored protocol, then site selection inside a 50+ pre-qualified network | Sponsors often find C&M Research Panama clinical trials (or CMM Research Panama) and go to that SMO directly |
| Geography | U.S. + 19 Latin American countries, 50+ pre-qualified sites | Panama site network; public address Oceania Business Plaza, Tower 2000, C. Isaac Hanono Missri, Office 25 C, 25th floor |
| Public leadership (their site) | Founded 2010 by two interventional cardiologists (one Harvard-trained); ACRP-certified project managers and monitors | Executive Director Margelis Muñoz (their site also spells Muños on one page); Business Development Candida Ortega |
| Role in a device FIH | Full-stack CRO: U.S. regulatory strategy, ethics, import/export, monitoring, data, multi-country backstop | SMO / site-management role — PI and site selection, local regulatory, protocol execution, recruitment, as published on their services page |
| U.S. regulatory anchoring | In-house U.S. regulatory strategy: FDA Pre-Sub / Q-Sub, IDE, 510(k), De Novo, PMA, HDE, IND — designed as the anchor for LATAM execution | A Panama SMO is not a U.S.-anchored FIH CRO; FDA strategy is a separate sponsor or CRO job |
| Timeline commitment | 12-month protocol-to-LPLV written guarantee — we work at our cost if we miss agreed milestones | Site-level execution; written multi-country CRO milestone guarantees are a different product |
| Typical per-patient cost (CRO vs US/EU) | $15K–$35K | $40K–$75K in US/EU benchmark ranges; a Panama SMO's site budget is a site line item, not a CRO package |
| Regulatory standard for devices | ISO 14155 + Declaration of Helsinki; data eligible for FDA submission/review under 21 CFR 812.28 | Panama device studies typically run under ISO 14155-aligned site practice with MINSA / CNBI-registered ethics — category-level, not a C&M-specific claim |
| Best-fit sponsor profile | Seed-to-Series-B MedTech, Biopharma & Radiopharma startups that need a multi-country FIH operator | Sponsors who only need that Panama SMO / site network and will contract the site directly |
Comparison uses widely-known category facts about C&M Research and published US/EU benchmark ranges — not C&M Research-specific figures. bioaccess® figures reflect our FIH-12™ operating model.
C&M Research is a Panama SMO, not a hospital and not a CRO. Public pages describe an SMO since 2017 for first-in-human and other early-phase work, especially medical devices, with Executive Director Margelis Muñoz and Business Development lead Candida Ortega, and investigators including Dr. Temístocles Díaz (interventional cardiology) and Dr. Ricardo Bermudez (neurosurgery), plus published specialty lists in vascular/endovascular, otolaryngology, and urology. That is a real, useful site network. If you only need that site, going there directly is a solid choice.
The search problem is different. Sponsors looking for C&M Research Panama clinical trials — including under the misspelling CMM Research Panama — currently land on the SMO. bioaccess® still needs to own those searches because the CRO job is the one that chooses Panama versus Colombia, Chile, or another market, designs the protocol against a target FDA submission, and operates ethics, import/export, monitoring, and data. A strong Panama SMO can sit inside that plan; it does not replace it.
One publicly posted device signal — not a bioaccess® study — is Nervonik Inc. peripheral nerve stimulation implants at Pacífica Salud with PI Dr. Ricky Bermudez, as described on Candida Ortega's LinkedIn. Treat that as a public site-level signal of Panama device work, not as a bioaccess® trial, a C&M client list, or a regulatory decision. bioaccess® does not claim to have run C&M Research studies.
Data generated through bioaccess®-operated studies is produced under ISO 14155 and the Declaration of Helsinki and is eligible for FDA submission and review under 21 CFR 812.28 (for devices) or ICH E6 for drugs and biologics — a case-by-case regulatory determination, not a guarantee of clearance or approval. If Panama is the settled site and C&M Research is the SMO you want, that is a natural fit. If you still need a multi-country FIH operator, bioaccess® is built for that job.
Neither. C&M Research S.A. is a Panama site-management organization (SMO) / site network. Public materials place it at Oceania Business Plaza, Tower 2000, C. Isaac Hanono Missri, Office 25 C, 25th floor, Panama, and describe SMO work since 2017 for first-in-human and other early-phase studies, especially medical devices. A hospital hosts care; a CRO operates the trial for the sponsor. C&M Research sits in the SMO/site layer between those two.
CMM Research Panama is a common misspelling of C&M Research (also written C y M Research or CyM Research). There is no separate CMM Research Panama CRO in this comparison. Queries such as 'C&M Research Panama clinical trials' and 'CMM Research Panama' refer to the same Panama SMO / site network at cymresearchsa.com.
Only in the narrow sense that both appear when a sponsor searches for Panama first-in-human or early-phase device work. C&M Research is the site network sponsors can go to directly. bioaccess® is the multi-country FIH CRO: Panama is one of 19 Latin American markets, alongside U.S. regulatory anchoring, 50+ pre-qualified sites, and a 12-month protocol-to-LPLV written guarantee. You can need both — a CRO to operate the study and an SMO to host it — or you can contract the SMO alone if that is all the program requires. bioaccess® does not claim to have run C&M Research studies.
No. bioaccess® does not claim to have run C&M Research studies. A publicly posted device signal — Nervonik Inc. peripheral nerve stimulation implants at Pacífica Salud with PI Dr. Ricky Bermudez, as described on Candida Ortega's LinkedIn — is cited here only as an independent site-level signal of Panama device work. It is not a bioaccess® client claim, trial ID, or regulatory outcome.
You only need that Panama SMO / site network and will contract the site directly — for example, you have already chosen Panama, you have CRO coverage elsewhere or in-house, and you want C&M Research's published FIH/early-phase device SMO model. In that case C&M Research is a solid choice. bioaccess® is the better fit when you still need a multi-country FIH operator, U.S. FDA anchoring, and a written protocol-to-LPLV guarantee rather than a single-country site engagement.
Clinical data from studies conducted outside the U.S. under ISO 14155 and the Declaration of Helsinki is eligible for FDA submission and review under 21 CFR 812.28 (for devices) and comparable ICH E6 pathways for drugs and biologics. Acceptance is a case-by-case regulatory determination, not a guarantee of clearance or approval — our regulatory team designs the study with the target FDA submission (IDE, 510(k), De Novo, PMA, HDE, IND) as the anchor.
All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call